Given that a subtle structural difference in the AML1 moiety could lead to a difference in the penetrance of disease and phenotypes of modeled MDS in mice (see description above), it is important to investigate AML1 mutants individually for their capacity amid BCR-ABL expression to induce BC-like disease in mouse models. The gene discussed is ABL1; the disease is myelodysplastic syndrome.